EGFR and HER2 inhibition in pancreatic cancer (Q39257360)

10 September 2017

title

EGFR and HER2 inhibition in pancreatic cancer (English)

1 reference

10 September 2017

1 reference

5

1 reference

10 September 2017

8

1 reference

10 September 2017

Naomi Walsh

1

1 reference

10 September 2017

Susan Kennedy

2

1 reference

10 September 2017

AnneMarie Larkin

3

1 reference

10 September 2017

Brendan Corkery

4

1 reference

10 September 2017

Martin Clynes

6

1 reference

10 September 2017

John Crown

7

1 reference

10 September 2017

publication date

18 October 2012

1 reference

Investigational New Drugs

10 September 2017

published in

1 reference

10 September 2017

volume

31

1 reference

10 September 2017

issue

3

1 reference

10 September 2017

page(s)

558-566

1 reference

10 September 2017

cites work

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9891-X

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9891-X

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9891-X

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9891-X

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9891-X

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9891-X

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9891-X

Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9891-X

In vitro and in vivo evidence that a combination of lapatinib plus S-1 is a promising treatment for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9891-X

Molecular prognostic markers in pancreatic cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9891-X

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9891-X

Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9891-X

Overexpression of HER2/neu oncogene in human pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9891-X

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9891-X

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9891-X

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9891-X

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9891-X

Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9891-X

Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9891-X

Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9891-X

KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9891-X

Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9891-X

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9891-X

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9891-X

Down-regulation of Platelet-Derived Growth Factor-D Inhibits Cell Growth and Angiogenesis through Inactivation of Notch-1 and Nuclear Factor-κB Signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9891-X

Lapatinib and gemcitabine for metastatic pancreatic cancer. A phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9891-X

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9891-X

The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9891-X

Nuclear localization of EGF receptor and its potential new role as a transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9891-X

Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9891-X

Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study

21 January 2018

1 reference

12 December 2020

Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer.

1 reference

12 December 2020

Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis

1 reference

12 December 2020

HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors

1 reference

12 December 2020

Usefulness of p16 and K-ras mutation in pancreatic adenocarcinoma and chronic pancreatitis differential diagnosis

1 reference

12 December 2020

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

1 reference

12 December 2020

The HercepTest and routine C-erbB2 immunohistochemistry in breast cancer: any difference?

1 reference

12 December 2020

Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms

1 reference

12 December 2020

Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms

1 reference

12 December 2020

Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells

1 reference

12 December 2020

10.1007/S10637-012-9891-X

Identifiers

DOI

1 reference

10 September 2017

1 reference